Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07733180) titled 'A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC' on July 22.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: BeOne Medicines
Condition:
Advanced Esophageal Squamous Cell Carcinoma
Metastatic Esophageal Squamous Cell Carcinoma
Intervention:
Drug: Tislelizumab
Drug: Oxaliplatin
Drug: Leucovorin
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 31, 2026
Target Sample Si...